RE: Avastin Thanks for this article South. It is a good read. Here is what I took note off:
"Today's approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years," said Chief Medical Officer Hal Barron. "This is the fifth tumor type for which Avastin has been approved in Europe, making it one of few biologic drugs indicated for multiple cancers."
This indicates their drug wasn't originally targeted for ovarian cancer, that it is a compliment to chemo, and that it's the first advance for ovarian cancer drugs in 15 years.
The more and more I dig into ovarian cancer, the more and more I learn how unique each patient is, how many different kinds of ovarian cancer there are, how many different areas are targeted as an area of treatment, how uniquely each patient reacts to a given drug, and how many routes of administration there are.
The quicker this moves the better, but if the drug receives regulatory approval, and shows statistically significant (stat sig) data, there will be a market for it.
Other things to note is that phase I is also there to confirm if ovarian cancer continues to be the ideal target for GAP-107B8. Other cancer patients will be accepted to examine the impact of GAP-107B8 on their cancer. Other cancers that could be accepted would be those where the treatment is administered through intraperitoneal injection (injection into the abdomen). These cancers are: pancreatic, colorectal, gastric, liver, and lung.
Tax loss selling ends today. I don't think it has been a big driver to date, as there hasn't been much selling into the bid over the last few weeks. I do however think there are a few people who have had bids in there hoping to get hit during tax loss selling.
Merry Christmas to all and a happy and healthy new year.